Drugs / BCMA Targeted CAR T-cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05430945 | Jun 2022 → Jun 2025 | plasma cell myeloma | Zhejiang University | Unknown | No outcome recorded |
| Phase 0 | NCT04670055 | Jan 2021 → Jan 2024 overdue | plasma cell myeloma | Zhejiang University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCMA Targeted CAR T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04670055 ↗ |
| Modality | Cell therapy | “B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T (CAR-T) therapy” PMID 39501801 ↗ Nov 2024 |
| Route | Intravenous | “Each subject receive BCMA Targeted CAR T-cells by intravenous infusion” NCT04670055 ↗ |